BL-M11D1 vs Gemtuzumab Ozogamicin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: CD33 · full Acute Myeloid Leukemia pipeline
BL-M11D1
Developed by SystImmune
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05924750 (registry estimate)
No aligned efficacy figure on record for this race.
Gemtuzumab Ozogamicin
Marketed by Pfizer
NCT00052299 · Phase 3 · completed
The trial was randomized and actively controlled, with 472 participants, but it was open-label rather than blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT03737955 (registry estimate)
Reported efficacy
Overall survival (OS) (four years): Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) (missed)
Result source: NCT00893399
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BL-M11D1 | Gemtuzumab Ozogamicin |
|---|---|---|
| OS, median | —Trial running · NCT07255872 | 27.9bNCT000495172 other results
|
| Complete remission | —Trial running · NCT07255872 | 69% vs 68.6%vs Ara-C+DaunomycinNCT00085709 |
| Event-free survival, median | —Trial running · NCT07255872 | —Not posted · NCT02473146 |
| Duration of response, median | —Trial running · NCT07255872 | —Not posted · NCT02473146 |
OS, median
- BL-M11D1
- —Trial running · NCT07255872
- Gemtuzumab Ozogamicin
- 27.9bNCT00049517
2 other results
- 2.8 NCT03727750
- 7.1 vs 10 NCT00052299
Complete remission
- BL-M11D1
- —Trial running · NCT07255872
- Gemtuzumab Ozogamicin
- 69% vs 68.6%vs Ara-C+DaunomycinNCT00085709
Event-free survival, median
- BL-M11D1
- —Trial running · NCT07255872
- Gemtuzumab Ozogamicin
- —Not posted · NCT02473146
Duration of response, median
- BL-M11D1
- —Trial running · NCT07255872
- Gemtuzumab Ozogamicin
- —Not posted · NCT02473146
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
BL-M11D1: no structured comparison results are available for Acute Myeloid Leukemia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BL-M11D1: 0 of 4 rows · Gemtuzumab Ozogamicin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gemtuzumab Ozogamicin |
|---|---|
| Dropout rate | 96.1%a NCT03727750 · Phase 4 · registry result, not featured evidence show 10 more results16.7%Ara-C+Daunomycin+Mylotarg NCT00085709 · Phase 3 · registry result, not featured evidence · combination —Induction 7 + 3 + G.O. NCT00085709 · Phase 3 · registry result, not featured evidence · combination —Post-consolidation G.O. NCT00085709 · Phase 3 · registry result, not featured evidence 23.1% NCT00551460 · Phase 2 · registry result, not featured evidence · combination —Cohort 1 NCT01698879 · Phase 2 · registry result, not featured evidence 0%Cohort 1 Version 2.0 NCT01698879 · Phase 2 · registry result, not featured evidence 0%Cohort 2 NCT01698879 · Phase 2 · registry result, not featured evidence 0% NCT00882102 · Phase 2 · registry result, not featured evidence · combination 0%GO1 Dose Level Phase 1 NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination 6.7%GO3 Dose Level Includes Phase 1 an NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —a NCT03727750 · Phase 4 · registry result, not featured evidence show 10 more results2.8%Ara-C+Daunomycin+Mylotarg NCT00085709 · Phase 3 · registry result, not featured evidence · combination —Induction 7 + 3 + G.O. NCT00085709 · Phase 3 · registry result, not featured evidence · combination —Post-consolidation G.O. NCT00085709 · Phase 3 · registry result, not featured evidence 1.3% NCT00551460 · Phase 2 · registry result, not featured evidence · combination —Cohort 1 NCT01698879 · Phase 2 · registry result, not featured evidence —Cohort 1 Version 2.0 NCT01698879 · Phase 2 · registry result, not featured evidence —Cohort 2 NCT01698879 · Phase 2 · registry result, not featured evidence — NCT00882102 · Phase 2 · registry result, not featured evidence · combination —GO1 Dose Level Phase 1 NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination —GO3 Dose Level Includes Phase 1 an NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 68%a NCT03727750 · Phase 4 · registry result, not featured evidence show 10 more results—Ara-C+Daunomycin+Mylotarg NCT00085709 · Phase 3 · registry result, not featured evidence · combination 16%Induction 7 + 3 + G.O. NCT00085709 · Phase 3 · registry result, not featured evidence · combination 24.4%Post-consolidation G.O. NCT00085709 · Phase 3 · registry result, not featured evidence 15.7% NCT00551460 · Phase 2 · registry result, not featured evidence · combination 15%Cohort 1 NCT01698879 · Phase 2 · registry result, not featured evidence —Cohort 1 Version 2.0 NCT01698879 · Phase 2 · registry result, not featured evidence 30%Cohort 2 NCT01698879 · Phase 2 · registry result, not featured evidence 2.5% NCT00882102 · Phase 2 · registry result, not featured evidence · combination 16.7%GO1 Dose Level Phase 1 NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination 16.7%GO3 Dose Level Includes Phase 1 an NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a febrile neutropenia 18% hypokalaemia 18% thrombocytopenia 18% NCT03727750 · Phase 4 · registry result, not featured evidence show 8 more resultsfebrile neutropenia 58.7% nausea 56.3% fatigue (asthenia, lethargy, malaise) 47.8% NCT00085709 · Phase 3 · registry result, not featured evidence · combination platelets 62.8% fatigue (asthenia, lethargy, malaise) 52.6% leukocytes (total wbc) 51.3% NCT00085709 · Phase 3 · registry result, not featured evidence ast, sgot 62.9% pain - head/headache 62.9% hemoglobin 57.1% NCT00551460 · Phase 2 · registry result, not featured evidence · combination grade 4 hematologic toxicity 100% g1/2 hepatic toxicity 10% grade i/ii infectous toxicity 10% NCT01698879 · Phase 2 · registry result, not featured evidence grade 4 hematologic toxicity 95% grade 3 infectous toxicity 30% grade i/ii infectous toxicity 25% NCT01698879 · Phase 2 · registry result, not featured evidence febrile neutropenia 50% infection 10% hemorhage 5% NCT00882102 · Phase 2 · registry result, not featured evidence · combination grade 3 enterocolitis 33.3% grade 3 sepsis 33.3% grade 3 bacteremia 16.7% NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination grade 3 febrile neutropenia 93.3% grade 3 hypertension 61.7% grade 3 sepsis 46.7% NCT03531918 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Gemtuzumab Ozogamicin
show 1 more result
show 1 more result
show 1 more result
show 2 more results
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BL-M11D1's landscape · Gemtuzumab Ozogamicin's landscape